Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca

Moderna

Pfizer

The vaccine developers are likely to pledge to observe high ethical standards in conducting clinical studies and manufacturing of the vaccines, the Wall Street report said.

Coronavirus Vaccine Makers May Make Joint Safety Pledge

Altimmune

Inovio Pharmaceuticals

Novavax

Vaxart

How to Invest in Coronavirus Vaccine Stocks

Apple

Flushing Financial

Home Depot

JPMorgan Chase & Co

Coca-Cola

Merck

Bancorp

Week 37 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

The company hopes to recruit 20,000 people from the region for the late-stage study.

Johnson & Johnson Aiming to Enroll One-Third of Phase 3 Trial Patients From Latin America

Sanofi

"Political considerations should be put aside by Republicans and Democrats," the vaccine manufacturers' draft statement says, according to the Journal.

Drugmakers seek to reassure public on coronavirus vaccine safety with joint pledge

BioNTech SE

GlaxoSmithKline

A quick approval would be nice, but the drugmakers are sticking to their scientific principals.

Moderna, Pfizer, Johnson & Johnson, And Others To Make Pledge in Response to Coronavirus Vaccine Political Pressure

It's time to prep your portfolio for the next market downturn.

2 Top Coronavirus Vaccine Stocks to Buy When the Next Market Crash Comes

Johnson & Johnson (NYSE: JNJ) said Thursday its unit Janssen’s COVID-19 vaccine candidate prevented severe COVID-19 disease in Syrian golden hamsters.

Johnson & Johnson Says Vaccine Prevented Severe COVID-19 Symptoms In Hamsters

It prevents severe forms of COVID-19 from developing, according to the researchers.

Johnson & Johnson Coronavirus Vaccine Candidate Shows Encouraging Results in Animal Trial

Johnson & Johnson’s potential coronavirus vaccine prevented severe illness in a small group of Syrian golden hamsters, the company announced Thursday.

Johnson & Johnson says coronavirus vaccine prevents severe illness in hamsters

Johnson & Johnson (JNJ) to halt the development of pimodivir, an investigational antiviral treatment of influenza A infection.

J&J to Stop Development of Influenza Candidate Pimodivir

Disney

Intel

McDonald's

Altria

Procter & Gamble

Let’s face it – blue-chip stocks aren’t the most popular investments in the new normal. But look a little deeper and you’ll find a stalwart that will suit multiple investment strategies.

10 Blue-Chip Stocks Ideal for Any Investor

Both are tough competitors in the coronavirus vaccine race, but which is a better overall investment?

Better Coronavirus Stock: AstraZeneca or Johnson & Johnson?

Arbutus Biopharma

America and the rest of the world is getting ready for a vaccine that will help protect public health against the COVID-19 pandemic.

As CDC Issues Notice, Stock Market Bets Which Company Gets First COVID-19 Vaccine FDA Approval

Shares of Johnson & Johnson  were down 1.1% in trading on Wednesday after the company said it had halted late-stage clinical trials for pimodivir, which it was testing as a treatment for people with influenza A. J&J said interim analyses from a Phase 3 trial indicated that the investigational therapy when combined with the standard of care was unlikely to have an added benefit for patients hospitalized with the virus.

J&J halts studies for experimental influenza A treatment

Johnson & Johnson: Safety Is Certain, Upside Is Questionable

Johnson & Johnson is financial fortress. That doesn’t mean that you can buy JNJ stock, throw it in a drawer, and forget about it.

Why Johnson & Johnson Remains a Risky Bet

Chevron

Endeavour Silver

Kindred Biosciences

Verizon

Walmart

Two Sample Breakout Stocks for Week 36 with better than 10% short-term upside potential. Now up an average 183.6% YTD.

Week 36 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

The United States Food and Drug Administration is willing to expedite the COVID-19 vaccine authorization process, including granting emergency use authorization to a candidate before it completes late-stage clinical trials, according to Chairman Stephen Hahn.

FDA Head Says A COVID-19 Vaccine Could Get Emergency Approval Without Phase 3 Trial Results: FT

Heat Biologics

COVID-19 vaccine stocks have gotten slammed this month.

Has The COVID-19 Vaccine Stock Bubble Burst?

Demand says we may need several players crossing the finish line.

In the Race for a Coronavirus Vaccine, Can There Be Multiple Winners?

Abbott Labs

Biogen

Here Are Warren Buffett's Favorite Coronavirus Stocks

Johnson & Johnson’s stock has gained 38% since the March 23 lows of this year, while Merck’s stock has slightly underperformed and gained 30% of its value. The lockdown in various parts of the world has had a negative impact on the pharmaceuticals industry worldwide due to deferment of elective.

Merck Vs JNJ, Merck's Got More Magic

Momenta Pharmaceuticals

Johnson & Johnson has increased its dividend for 58 years in a row (a dividend king) and presently has a yield of 2.7%, which is above average.

Johnson & Johnson: Accelerating Their Virus Vaccine Development And The Buy Of Momenta With Debt Is A Good Move

Gilead Sciences

Convalescent plasma contains antibodies that can fight off the disease faster and prevents COVID-19 patients from getting severely ill.

News for Johnson & Johnson Stock (JNJ)